Q4FY24 Concall highlights:
- Ebidta declined due to high RM cost (platin which is a gold n platinum derivative)
- Platin cost comprises 14-15% sales
- Platin can’t be manufactured in house.
- Yearly sales breakup:
- Branded: 89 Cr (margin 33-36%)
- CDMO: 140 Cr (margin 15-17%)
- Exports: 46 Cr (margin 28-32%)
- API : 21 Cr (margin 22-23%)
- Derma: 6.83 Cr - halfyearly sales breakup:
- Branded: 41.5 Cr
- CDMO: 68 Cr
- Export: 30 Cr
- API: 11 Cr
- Derma: 3.3 Cr - Ebidta will try to bring to 26% in FY25
- Cosmotology:
- division posted net loss
- guidance FY25 min sales 14-15 Cr
- gross margin is 65%
- plant setup initiate by Fy25-26 ( 30 - 35 Cr)
- recently launched 5 products (haircare, sunscreen, moisturizer)
- Will focus on hair product segment
- Future target 35% of business
- Dr prescribed medicine after Dr approves. - Cleared audit n received registration cert from Urasia
- Cytotoxic syrup facility started
- Own brand, injectable: Oral = 43 : 57
- FY25 guidance 25-30% sales.
- 70% Api in house manufactured.
- 2-3 months will migrate to main board, process already initiated.
- export business target 35% business in future.
Subscribe To Our Free Newsletter |